HTG Molecular Diagnostics, Inc. Price & Performance (HTGM)

HTG Molecular Diagnostics (HTGMQ) has seen a notable uptick in investor interest this week, with a 36% increase in page views and heightened social media mentions. However, the stock remains down 96% over the past year, underperforming both its sector and the broader US market.12

HTG Molecular Diagnostics reported trailing twelve-month losses of $20.15 million against $6.21 million in revenue, with gross profit still negative. Analysts highlight the company's persistent financial struggles, further compounded by underperformance versus industry peers and ongoing volatility in its share price.23

HTG Molecular Diagnostics continues to advance its drug discovery platform, integrating RNA profiling and machine learning. The company has reported interest from pharmaceutical partners and is progressing toward preclinical development of new compounds, aiming to leverage collaborations in oncology and neurodegenerative research.45